Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;25(1-2):1-8.
doi: 10.1089/ten.TEA.2018.0138. Epub 2018 Sep 4.

An Overview of the Tissue Engineering Market in the United States from 2011 to 2018

Yu Seon Kim  1 , Mollie M Smoak  1 , Anthony J Melchiorri  2 , Antonios G Mikos  1   2
Affiliations

An Overview of the Tissue Engineering Market in the United States from 2011 to 2018

Yu Seon Kim et al. Tissue Eng Part A. 2019 Jan.

Abstract

This report seeks to provide an update of the current landscape of the tissue engineering market in the United States from an unbiased point of view by analyzing the financial reports provided by tissue engineering companies, as well as data from publicly available clinical trials with relevant tissue engineering applications.

Keywords: company; industry; market; regenerative medicine; tissue engineering.

PubMed Disclaimer

Conflict of interest statement

No competing financial interests exist.

Figures

<b>FIG. 1.</b>
FIG. 1.
Distribution of tissue engineering companies in the United States. Companies were plotted on a map of the U.S. based on the location of their principal executive office (created through mapchart.net©).
<b>FIG. 2.</b>
FIG. 2.
Total sales by product type. Total sales from tissue engineering companies (A) and sales of tissue engineering products within tissue engineering companies (B) were sorted by product type.
<b>FIG. 3.</b>
FIG. 3.
Breakdown of tissue engineering company information. Operating expenses (A) were reported for companies by product type. The number of companies (B) and the number of employees (C) within each product category were also reported. R&D, research and development.
<b>FIG. 4.</b>
FIG. 4.
Spending by development stage. Operating expenses were reported for companies by product type and development stage. The spending was categorized based on company product type within commercial (A), clinical (B), and preclinical (C) stages. The number of companies was also reported based on their development stage (D).
<b>FIG. 5.</b>
FIG. 5.
Clinical trials. Information was gathered about clinical trials active between June 2011 and March 2018. The number of clinical trials in each clinical trial phase was reported (A). The sponsors of each clinical trial were reported (B). The clinical trials were organized into categories based on the therapeutic applications (C).
See this image and copyright information in PMC

References

    1. Langer R., and Vacanti J.P. Tissue engineering. Science 260, 920, 1993 - PubMed
    1. Jaklenec A., Stamp A., Deweerd E., Sherwin A., and Langer R. Progress in the tissue engineering and stem cell industry “are we there yet?” Tissue Eng B Rev 18, 155, 2012 - PubMed
    1. Mason C., and Manzotti E. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen Med 5, 307, 2010 - PubMed
    1. Mason C., Brindley D.A., Culme-Seymour E.J., and Davie N.L. Cell therapy industry: billion dollar global business with unlimited potential. Regen Med 6, 265, 2011 - PubMed
    1. Lysaght M.J. Product development in tissue engineering. Tissue Eng 1, 221, 1995 - PubMed

Publication types

LinkOut - more resources